

June 12, 2024

The General Manager

BSE Limited

Corporate Relationship Department Phiroze Jeejeebhoy Towers

Dalal Street Mumbai- 400 001 The Manager

National Stock Exchange of India Limited

Listing Department Exchange Plaza 5th Floor, Plot No. C-1, Block-G

Bandra-Kurla Complex, Bandra(E)

Mumbai-400 051

BSE Scrip Code: 532281 **NSE Scrip Code: HCLTECH**

Subject: Release: "Olympus and HCLTech expand Engineering and R&D partnership"

Dear Sir/ Madam,

Enclosed please find a Release issued by the Company on the above subject.

This is for your information and records.

Thanking you,

Yours faithfully, For HCL Technologies Limited

Manish Anand Company Secretary

Encl:a/a





Olympus and HCLTech expand Engineering and R&D partnership

Announce dedicated center in Hyderabad, India to advance Olympus' global product innovation journey

TOKYO and NOIDA, India, June 12, 2024—HCLTech, a leading global technology company, and Olympus Corporation (Olympus), a global MedTech company, have expanded their strategic partnership to enable advanced and affordable healthcare for patients through cutting-edge engineering technologies.

HCLTech will leverage its global leadership in Engineering and R&D services along with artificial intelligence (AI) based solutions to provide speed and scale to Olympus' global product development journey.

HCLTech will establish a dedicated product innovation center in Hyderabad, India to serve Olympus' operations across US, Europe, Middle East and Africa. The center is expected to commence operations by July 2024 and boost Olympus' business expansion plans and drive advancements in medical technology.

HCLTech and Olympus share a decade-long partnership in core Engineering and R&D, spanning product engineering, software engineering, product sustenance, risk and regulatory services. HCLTech serves Olympus from its global delivery centers in India and Vietnam.

"It is with great pleasure and excitement that we announce this agreement with HCLTech, with whom we share a decade-long partnership in core Engineering and R&D services. I am confident that our collaboration will enhance Olympus' engineering capabilities and unlock new innovations that enable quality healthcare through technology," said Andre Roggan, Chief Technology Officer, Olympus.

"HCLTech is focused on bringing together the best of technology and its people to supercharge progress for its clients. We look forward to deepening our collaboration with Olympus, adding tangible value to its new product development and growth with our expertise in MedTech product engineering," said Hari Sadarahalli, Corporate Vice President and Head of Engineering and R&D Services, HCLTech.

HCLTech is partner to 100+ of the top 250 engineering R&D spenders globally. The company has been ranked #1 engineering services provider in Everest Group's 2023 PEAK Matrix Provider of the Year™ Awards and rated a leader in IDC MarketScape: Worldwide Software Engineering Services 2023 Vendor Assessment



About Olympus

At Olympus, we are committed to Our Purpose of making people's lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide best-in-class solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit olympus-global.com and follow our global X account: @Olympus_Corp.

About HCLTech

HCLTech is a global technology company, home to more than 227,000 people across 60 countries, delivering industry-leading capabilities centered around digital, engineering, cloud and AI, powered by a broad portfolio of technology services and products. We work with clients across all major verticals, providing industry solutions for Financial Services, Manufacturing, Life Sciences and Healthcare, Technology and Services, Telecom and Media, Retail and CPG and Public Services. Consolidated revenues as of 12 months ending March 2024 totaled \$13.3 billion. To learn how we can supercharge progress for you, visit holtech.com.

For further details, please contact:

HCLTech

Meenakshi Benjwal, Americas meenakshi benjwal@hcltech.com

Elka Ghudial, EMEA elka.ghudial@hcltech.com

James Galvin, ANZ james.galvin@hcltech.com

Siddhartha Bhatnagar, India bhatnagars@hcltech.com